Cerus Funding & Investors
Concord, CA
Cerus Corporation develops systems designed to enhance the safety of blood transfusions. The Company's systems inactivate pathogens in blood components and inactivate white blood cells, which are responsible for a variety of adverse transfusion reactions. Cerus' platform technologies prevent viral, bacterial, and cellular replication.
cerus.comTotal Amount Raised: $235,800,000
Cerus Funding Rounds
Post Ipo Equity
$63,300,000
Grant
$15,000,000
Post Ipo Equity
$57,500,000
Post Ipo Equity
$70,000,000
Post Ipo Debt
$30,000,000
Post Ipo Debt Investors
Oxford FinanceIPO
Unknown
Funding info provided by Diffbot.